EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy

Jeroen Hendrikus Jacobus Paulissen iD, Alexander Victor van Schoonhoven iD, Emma Olin iD, Arjan Jacobus Postma, Zacharie Mbanya, Kyle John Dunton, Maarten Jacobus Postma iD, Marinus van Hulst iD, Roel Donald Freriks iD

Advances in Therapy · 2025-01 · 42 (1) · 322-333

DOI: 10.1007/s12325-024-03033-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, online erschienen am 12.11.2024. Verfasst von Jeroen Hendrikus Jacobus Paulissen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands. j.h.j.paulissen@umcg.nl. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universitair Medisch Centrum Groningen, Daiichi Sankyo International, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In 2021, breast cancer affected 75,619 women in Denmark. Approximately 50% of breast cancers are considered human epidermal growth factor receptor 2 (HER2)-low. The DESTINY-Breast04 (DB-04) trial led to European Medicines Agency (EMA) approval of trastuzumab deruxtecan (T-DXd) as a treatment for patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Moreover, the Danish Breast Cancer Group guidelines recently included T-DXd as a treatment for HER2-low metastatic breast cancer. This economic evaluation aims to estimate the cost-effectiveness of T-DXd for the approved EMA indication in Denmark. METHODS: A three-state-progression-free, post-progression, and death-partitioned survival model was developed to estimate the cost-effectiveness of T-DXd versus treatment of physician's choice over a lifetime horizon following the Danish Medicines Council guidelines. Clinical data were gathered from the DB-04 trial, and cost and resource use data were sourced from the literature. Sensitivity and scenario analysis were conducted to explore uncertainty. RESULTS: T-DXd led to 0.78 incremental quality-adjusted life years (QALYs) gained and incurred DKK 621,325 in incremental costs compared to the treatment of physician's choice. This resulted in an incremental cost-effectiveness ratio of DKK 795,181 per QALY gained, which falls below the willingness-to-pay threshold. Sensitivity and scenario analyses showed the robustness of the deterministic result, with T-DXd remaining cost-effective. CONCLUSION: Our study demonstrates that T-DXd is a cost-effective treatment for patients with HER2-low unresectable or metastatic breast cancer who have received prior chemotherapy in Denmark.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabAntineoplastic Agents, ImmunologicalHumansFemaleCost-Benefit AnalysisErb-b2 Receptor Tyrosine KinasesDenmarkQuality-Adjusted Life YearsNeoplasm MetastasisMiddle AgedCamptothecinImmunoconjugates

Stichwörter der Autor:innen

Cost-effectivenessHER2-lowMetastatic breast cancerTrastuzumab deruxtecan

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, ImmunologicalCamptothecinImmunoconjugatesERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands. j.h.j.paulissen@umcg.nl.
  • Asc Academics, Groningen, The Netherlands. j.h.j.paulissen@umcg.nl.
  • Department of Health Sciences, University Medical Center Groningen, Groningen, The Netherlands.
  • Asc Academics, Groningen, The Netherlands.
  • AstraZeneca, Stockholm, Sweden.
  • AstraZeneca Plc., Cambridge, UK.

ORCID-Profile: Jeroen Hendrikus Jacobus Paulissen, Alexander Victor van Schoonhoven, Emma Olin, Maarten Jacobus Postma, Marinus van Hulst, Roel Donald Freriks

Förderung

  • Universitair Medisch Centrum Groningen
  • Daiichi Sankyo International
  • AstraZeneca

Zitieren

APA

Paulissen, J. H. J., van Schoonhoven, A. V., Olin, E., Postma, A. J., Mbanya, Z., Dunton, K. J., Postma, M. J., van Hulst, M., & Freriks, R. D. (2025). Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy. Advances in Therapy, 42(1), 322-333. https://doi.org/10.1007/s12325-024-03033-2

Vancouver

Paulissen JHJ, van Schoonhoven AV, Olin E, Postma AJ, Mbanya Z, Dunton KJ, et al. Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy. Advances in Therapy. 2025;42(1):322-333. doi:10.1007/s12325-024-03033-2

BibTeX
@article{Paulissen2025,
  author = {Paulissen, Jeroen Hendrikus Jacobus and van Schoonhoven, Alexander Victor and Olin, Emma and Postma, Arjan Jacobus and Mbanya, Zacharie and Dunton, Kyle John and Postma, Maarten Jacobus and van Hulst, Marinus and Freriks, Roel Donald},
  title = {Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy},
  journal = {Advances in Therapy},
  year = {2025},
  volume = {42},
  number = {1},
  pages = {322--333},
  doi = {10.1007/s12325-024-03033-2}
}
Kostenlos starten →